Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
Trial status:Recruiting
Trial ID:
BNT327-02
NCT ID:
EudraCT ID:
N/A
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
BioNTech SE
Recruiting
Trial Details
This study is a Phase II, multi-site, randomized, open-label clinical study to evaluate the safety, efficacy, and pharmacokinetics (PK) of BNT327 at two dose levels in combination with chemotherapeutic agents in the first- and second-line treatment of participants with locally advanced/metastatic triple-negative breast cancer (mTNBC).
Medical Condition
Trial Drug
See more
Phase
Phase 2
Type
Interventional
Estimated Enrolment
70
Estimated Trial Date
Aug 2024 - Mar 2025
Trial Participant Requirements
Age
18+ years
Sex
Female & Male
Healthy Volunteers
No
Trial Locations
Location
Status
Location
Arizona Oncology Associates, PC
Tucson, Arizona, United States, 85711
Status
Recruiting
Location
Beverly Hills Cancer Center
Beverly Hills, California, United States, 90211
Status
Recruiting
Location
Valkyrie Clinical Trials
Los Angeles, California, United States, 90067
Status
Recruiting
Location
Saint John's Health Center - John Wayne Cancer Institute (JWCI)
Santa Monica, California, United States, 90404-2312
Status
Recruiting
Location
Rocky Mountain Cancer Centers (RMCC)
Denver, Colorado, United States, 80220
Status
Recruiting
Location
Yale University - Yale Cancer Center
New Haven, Connecticut, United States, 06520
Status
Recruiting